Antibody-drug conjugates (ADCs) are one of the fastest-growing therapeutic
modalities, with 12 FDA-approved ADCs and more than 280 different ADCs in
clinical development. Despite their success, significant hurdles remain. Notably,
translating preclinical findings to the clinic remains challenging. Hematological
toxicities are commonly associated with many ADCs and may arise from the direct
killing of hematopoietic cells by the ADC itself or indirectly from payload re-leased
elsewhere in the body.
